Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 17/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5465695 | 0.90 | CHEK1 (0.44) | CHEK1DRD4 | |
| SCHEMBL5475761 | 0.84 | CHEK1 (0.52) | CHEK1 | |
| SCHEMBL5475825 | 0.84 | CHEK1 (0.55) | CHEK1 | |
| SCHEMBL5470085 | 0.83 | CHEK1 (0.51) | CHEK1 | |
| SCHEMBL5469819 | 0.82 | CHEK1 (0.54) | CHEK1DRD4 | |
| SCHEMBL5470160 | 0.81 | CHEK1 (0.55) | CHEK1 | |
| SCHEMBL5469004 | 0.81 | CHEK1 (0.55) | CHEK1 | |
| SCHEMBL5470108 | 0.80 | CHEK1 (0.55) | CHEK1 | |
| SCHEMBL5465275 | 0.77 | CHEK1 (0.62) | CHEK1 | |
| SCHEMBL5472919 | 0.77 | CHEK1 (0.55) | CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | claimed |
| JP-2006520397-A | — | — | 2006-09-07 | — | — | JP | claimed |
| EP-1613625-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | claimed |
| WO-2004081008-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | WO | claimed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | CHEK1 13/4885DRD4 3553/4885VEGFA 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.